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Foamy viruses are nonpathogenic retroviruses that offer unique opportunities for gene transfer into various cell types
including hematopoietic stem cells. We used a simian foamy virus type 1 vector (SFV-1) containing a LacZ reporter gene with
a titer of 1–5  106 viral particles/ml that was free of replication-competent retrovirus to transduce human umbilical cord
blood CD34 cells. Transduced CD34 cord blood cells were transplanted into NOD/SCID mice and plated in serum-free
methylcellulose culture to determine the transduction efficiency of human hematopoietic progenitor cells. A transduction
efficiency of about 20% was obtained. At 6–10 weeks posttransplantation, human hematopoietic cell engraftment and marking
were determined. Marrow from transplanted mice demonstrated human cell engraftment by the presence of human (CD45)
cells containing both CD19 lymphoid and CD33 myeloid cells. Serial sampling of NOD/SCID bone marrow revealed the
presence of 6.7–14.0% CD45 cells at 6 weeks posttransplant as compared to 3.6–27.2% CD45 cells at 9–10 weeks
posttransplant. Human progenitors examined from NOD/SCID bone marrow cells 9 weeks posttransplant revealed from 7.4
to 25.9% of the colonies exhibiting X-gal staining. Our study demonstrates the ability of a simian foamy virus vector to
transduce the SCID-repopulating cell and offers a promising new gene delivery system for use in hematopoietic stem cellINTRODUCTION
Foamy viruses are retroviruses that offer several
unique features for gene transfer. These viruses are
found in many mammalian species and appear to be
ubiquitous. Foamy viruses have a broad host range and
can efficiently be propagated in various cell types of
several species. Others and we have shown that cul-
tured epithelial and fibroblast cells as well as lymphoid
and neural-originated cells support the growth of foamy
viruses (Mergia et al., 1996; Mikovits et al., 1996). A
foamy virus isolate from one species can infect several
mammalian species (Hooks and Detrick-Hooks, 1981). In
the infected animals the virus can be recovered from
many organs including blood cells and brain tissue
(Hooks and Detrick-Hooks, 1981). However, no disease
has been correlated to foamy virus infection in naturally
or experimentally infected animals (Flugel, 1991; Mergia
and Luciw, 1991; Weiss, 1988). Animal caretakers acci-
dentally infected with simian foamy virus also remain
healthy while virus persists in the infected individuals
(Callahan et al., 1999; Heneine et al., 1998; Schweizer et
al., 1997). These features of foamy viruses offer unique
1 To whom reprint requests should be addressed at Department of229opportunities to develop an ideal vector system for hu-
man gene therapy.
Several versions of foamy virus vectors based on
SFV-1 and human foamy virus (HFV) capable of gene
transfer were developed (Mergia and Wu, 1998; Russell
and Miller, 1996; Schmidt and Rethwilm, 1995; Wu et al.,
1998; Wu and Mergia, 1999). These vectors contain the
5-untranslated leader region and the 5 end of the gag
gene which contain important cis-acting elements. Sim-
ilar to other retroviruses, this region is complex, with
specific sequences that have features of secondary
structure. For retroviruses, the 5-untranslated region is
implicated in viral RNA genome encapsidation, diploid
genome dimerization, and efficient gag translation
(Berkowitz et al., 1996; Linial and Miller, 1990; Miele et al.,
1996). Although the encapsidation signal for foamy vi-
ruses is unknown, the 5-untranslated region serves for
diploid genome dimerization and efficient gag translation
(Erlwein et al., 1997; Heinkelein et al., 2000; Russell et al.,
2001). Recent studies on foamy virus vector construction
suggest that additional sequences required for foamy
virus vector transfer are found in the 3 end of the pol
gene (Erlwein et al., 1998; Heneine et al., 1998; Wu et al.,
1998). The role of these sequences in foamy virus repli-
cation and vector construction remains to be determined.gene therapy. © 2002 Elsevier Science (USA)
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foamy virus is present virtually in all cells including
nondividing cells. Transduction of nondividing cells by
the HFV vector remains controversial. Bieniasz et al.
demonstrated that foamy virus replication is cell cycle
dependent (Bieniasz et al., 1995). Others have shown
that the foamy virus DNA can enter the nucleus of
G1/S phase arrested cells (Saib et al., 1997). However,
the study found no viral gene expression. Although low
efficiency, Russell and Miller were able to deliver and
express a transgene into stationary cells using HFV
vector and the efficiency of gene expression was
higher than that of the MuLV vector (Russell and Miller,
1996). Our recent studies with SFV-1 vector, however,
clearly demonstrated efficient gene transductions that
are equivalent to the lentivirus vectors in a variety of
nondividing cells (Mergia et al., 2001). Because SFV-1
vector transduces a wide variety of vertebrate cells by
integration of the vector genome and transduces sta-
tionary cultures efficiently, they may be more effective
at transferring genes into the human hematopoietic
stem cells. In support of this notion Vassilopoulos et
al. reported that murine hematopoietic progenitors
were transduced by a single HFV vector stock and that
mice that received transduced murine bone marrow
cells expressed the vector-encoded transgene in all
major hematopoietic cell lineages (Vassilopoulos et
al., 2001). Others, however, indicated low-level expres-
sion of functional foamy virus receptor on hematopoi-
etic progenitor cells (von Laer et al., 2001). Here, we
present the first report of efficient transduction of
human CD34 cells capable of engrafting NOD/SCID
mice by a simian foamy virus vector containing the
LacZ marker gene.
RESULTS
SFV-1 vector transduction of hematopoietic
progenitors assayed in vitro
To evaluate gene transfer and expression in trans-
duced human CD34 cord blood cells, helper-free SFV-1
vectors expressing the LacZ reporter gene were made by
transfecting SFV-1 vector and packaging plasmid into
293T cells. Transient high-titer vector was achieved in
the SFV-1 system by replacing the U3 region with the
human cytomegalovirus (CMV) immediate-early gene
promoter (Fig. 1). Using this vector system, viral stocks
with titers ranging from 1.0 to 5.0  106 transducing
units/ml were obtained. Since our vector system lacks
the tas gene, no replication-competent virus was gener-
ated (data not shown). This titer compares favorably with
titers of amphotropic or GALV-pseudotyped oncoretrovi-
ral vectors reported in the past (Miller et al., 1993).
This foamy virus vector was used to transduce human
cord blood CD34 cells on fibronectin-coated plates.
Since transgene expression immediately following trans-
duction may not reflect the level of stable viral integration
(Gallardo et al., 1997; Haas et al., 2000), colony-forming
cell assays were performed to test the efficiency of
stable gene transfer into clonogenic erythroid, myeloid,
and mixed progenitor cells. Transduced SFV-1 cord
blood CD34 cells were plated in methylcellulose and
mean transduction efficiencies determined. After stain-
ing for LacZ expression, we routinely obtained about 20%
transduction efficiency (Table 1). Single as well as mul-
tilineage colonies stained positive for LacZ gene expres-
sion, indicating that transgene expression was main-
tained over 14 days (Fig. 2).
SFV-1 vector transduction in SCID-repopulating cells
(SRCs)
Several studies have demonstrated that in vitro assays
do not predict the in vivo engraftment activity of human
hematopoietic stem cells. We decided therefore to use
the SCID-repopulating cell assay with NOD/SCID recip-
ient mice that had been previously irradiated at 3.0 cGy
as a surrogate measure of gene transfer into engrafting
human hematopoietic stem cells. We performed two in-
TABLE 1
Percentage -gal Colonies Were Scored After 14 Days in Methyl-
cellulose Cultures of SFV-1-Transduced CD34 Human Cord Blood
Cells
-gal colony Total colonies %-gal colonies
10 46 21.8
10 43 22.3
6 48 12.5
Mean 19.2
FIG. 1. Schematic representations of SFV-1 vector (pCV7-9) contain-
ing the LacZ reporter gene and packaging construct (pCGPET) used
to generate SFV-1 vector stocks. The provirus genome of SFV-1 is
shown in the top panel. CMV is the promoter of the human cytomeg-
alovirus immediate-early gene.
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dependent experiments to determine if transgene ex-
pression could be found in SRCs. In each experiment,
1–1.5  105 SFV-1-transduced CD34 cells were trans-
planted into NOD/SCID recipient mice. Six to 10 weeks
later, the presence of engrafted human cells expressing
the human CD45 antigen within mouse bone marrow
was analyzed by FACS. Figure 3 shows a typical FACS
analysis of engrafted cells showing that the CD45 cell
population contained both human myeloid CD33 cells
and human lymphoid CD19 cells.
We further examined gene transduction into long-term
engrafted human cells by terminating transplanted NOD/
SCID mice at 9–10 weeks posttransplantation. In addi-
tion, the presence of transduced human colony-forming
progenitor cells within the bone marrow of transplanted
NOD/SCID recipient mice was assayed subsequently
(Tables 2 and 3). In the first experiment (Table 2), any-
where from 3.6 to 27.3% of the bone marrow cells ana-
lyzed were labeled with anti-CD45 antibody at 9 weeks
following transplantation. When these cells were placed
in a colony assay, the percentage of LacZ human
colonies ranged from 0.1 to 20% of the total colonies
observed. These LacZ colonies included CFU-GM,
CFU-Meg, BFU-E, and CFU-mix, indicating that multiple
lineages could be transduced by this SFV-1 vector. No
LacZ colonies were seen in control cultures plating
cells obtained from NOD/SCID mice receiving nontrans-
duced human CD34 cells. This experiment was re-
peated using 6 more transplanted NOD/SCID mice (Ta-
ble 3). In this study, bone marrow cells obtained from 4 of
the 6 mice showed detectable human cell engraftment of
greater than 1.0% CD45 cells at 10 weeks following
transplantation. The percentage of colonies staining pos-
itive for LacZ ranged from 11.8 to 25.9%. Once again all of
the different colony types were observed staining blue,
indicating multilineage expression of the transgene. The
numbers of engrafted human progenitors containing the
LacZ reporter gene were in good correlation with the
FIG. 2. Multilineage repopulation capacity of transduced SCID-repopulating cells. Cells from the bone marrow of a NOD/SCID mouse transplanted
with LacZ-transduced human CD34 cells and examined by flow cytometry 10 weeks after transplantation. The numbers in the upper right quadrants
show the percentages of human CD33myeloid or human CD19 lymphoid cells found within the CD45 population. Quadrants were set according
to isotype-matched negative control stainings.
FIG. 3. PCR analysis of DNA obtained from the bone marrow cells of
6 NOD/SCID mice receiving LacZ-transduced human CD34 cells
shown in Table 3. Each Lane contained DNA amplified with primers
specific for LacZ gene. Lanes show negative () and positive ()
controls and six DNA samples from bone marrow of 6 NOD/SCID mice.
Positive control is DNA-amplified from vector pCV7-9. The size of the
PCR product is given in nucleotide (nt). M represents a 1-kb ladder size
marker.
TABLE 2
Experiment 1: Analysis of Bone Marrow Cells Obtained from NOD/
SCID Mice Transplanted with LacZ-Transduced CD 34 Cord Blood
Cells
Animal Time of analysis % CD 45 % -gal colonies
A1 6 weeks 6.7 NAa
B2 6 weeks 14.0 NA
B3 6 weeks 9.0 NA
B4 6 weeks 9.8 NA
B5 6 weeks 13.8 NA
A1 9 weeks 3.6 0.1
B2 9 weeks 20.2 11.5
B3 9 weeks 20.6 19.5
B4 9 weeks 27.3 20.0
B5 9 weeks 16.4 7.4
a NA, not applicable.
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percentage of CD45 cells analyzed, suggesting that
functional multipotential human hematopoietic stem
cells can be readily transduced by SFV-1 vectors and
repopulate in NOD/SCID mice.
Transduction of human CD34 cells with LacZ was
confirmed using standard polymerase chain reaction
(PCR) and reverse transcription (RT) PCR amplification in
both DNA and RNA extracts obtained from the bone
marrow of the transplanted NOD/SCID mice (Figs. 3 and
4). A signal representing the presence of DNA se-
quences specific for -galactosidase was seen in all six
samples obtained from experiment 2 (Fig. 3). Further-
more, total RNA obtained from the bone marrow cells of
each of these same NOD/SCID mice was analyzed by
RT-PCR for the presence of -galactosidase-specific
RNA (Fig. 4). A signal representing the presence of -gal-
galactosidase RNA was also seen for each sample ob-
tained from the NOD/SCID mice.
DISCUSSION
In this study, we have shown that a vector developed
from simian foamy virus can efficiently transduce human
CD34 hematopoietic progenitors obtained from human
umbilical cord blood. This study also shows that NOD/
SCID recipients of transduced CD34 human hemato-
poietic cells express the vector-encoded transgene in all
hematopoietic cell lineages analyzed. Transduction at
the human hematopoietic stem cell level was suggested
by the long-term transgene expression in transplant re-
cipients. This is in contrast to the silencing problem of
transgene expression over time reported for murine leu-
kemia virus (MLV) vectors (Challita and Kohn, 1994;
Palmer et al., 1991). We did not observe significant si-
lencing in our experiments which demonstrated the
presence of X-gal staining human colony formation in the
bone marrow of NOD/SCID mice 10 weeks after trans-
plantation. We also observed relatively high transduction
efficiencies (about 20%) which are comparable to those
reported using human lentiviral based vectors (Miyoshi
et al., 1999).
Current gene delivery systems are mainly based on
retroviruses, adenovirus, adeno-associated virus (AAV),
and nonviral methods such as liposome-mediated gene
transfer (Robbins et al., 1998; Romano et al., 2000; Smith,
1999; Wolfe et al., 1999; Wu and Ataai, 2000). The problem
with nonviral vectors is that the transfer of DNA to the
nucleus is a very inadequate process in vivo (Callahan et
al., 1999; Heneine et al., 1998; Sandstrom et al., 2000;
Schweizer et al., 1995, 1997). Adenovirus vectors do not
have the machinery necessary to integrate into the host
genome (Robbins et al., 1998; Romano et al., 2000; Zhang
and Russell, 1996). Although the current AAV vectors are
capable of integration into the host cell genome, the
efficiency of vector integration appears to vary with the
cell type targeted (Robbins et al., 1998; Romano et al.,
2000; Zhang and Russell, 1996). Since the life cycle of
retroviruses involves integration of the genome into the
host DNA, these viruses provide an efficient means of
gene delivery. Several of the gene therapy studies using
retroviral vectors are based on the murine leukemia virus
(MuLV) (Anderson, 1998; Gunji et al., 2000; Morgan and
Blaese, 1999; Mountain, 2000). These vectors, however,
appear to be inefficient in vivo (Culver et al., 1990, 1991;
Morgan et al., 1994; Naldini et al., 1996; Woffendin et al.,
1994). Vectors based on lentiviruses such as HIV are
promising since they can infect both dividing and nondi-
viding cells (Akkina et al., 1996; Naldini et al., 1996).
Although the feasibility of lentiviruses in human gene
therapy is still being exploited using animal models,
lentivirus vectors suffer from the potential risk of causing
TABLE 3
Experiment 2: Analysis of Bone Marrow Cells Obtained from NOD/
SCID Mice at 10 Weeks Following Transplantation with -gal- Trans-
duced CD 34 Cord Blood Cells
Animal # %CD 45 %-gal colonies
1 8.7 20.2
3 20.9 25.9
4 13.0 11.8
5 0.9 0.1
7 1.0 0.1
8 21.0 18.5
FIG. 4. RT-PCR analysis of RNA obtained from the bone marrow cells of 6 NOD/SCID mice receiving LacZ-transduced human CD34 cells shown
in Table 3. Each Lane contained DNA amplified with primers specific for LacZ transcripts. / equals positive or negative for the addition of reverse
transcriptase. Lanes show negative (N) and positive (P) controls and the six RNA samples from bone marrow of 6 NOD/SCID mice. Positive control
is DNA-amplified from vector pCV7-9. The size of the PCR product is given in nucleotide (nt). M represents a 1-kb ladder size marker.
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disease in humans. Vectors based on animal lentiviruses
have been implicated as an alternative to HIV vectors for
human gene therapy. However, the recent report that FIV
can infect cynomolgus macaques (Macaca fasicularis)
with clinical signs, including depletion of CD4 cells and
weight loss, that are consistent with FIV infection indi-
cates the risk associated with the usage of animal len-
tivirus-based vectors for human gene therapy (Johnston
et al., 2001). As an alternative to lentivirus, the SFV-1
vector system may provide a safe and efficient means of
gene delivery, satisfying current concerns with existing
retrovirus vectors. We previously established that SFV-1
vectors transduce nondividing cells efficiently, implicat-
ing that quiescent nondividing cells such as human stem
cells are prone to SFV-1-mediated gene transfer. Simi-
larly, expression of cellular SFV receptor molecules on
hematopoietic stem cells may also account for the im-
proved transduction efficiency although the expression
of these receptors is not known. Our finding of efficient
transduction of human SCID-repopulating cells in this
report strengthens the notion that foamy virus vectors
are ideal for human gene therapy. Future studies will
determine whether vectors based on nonpathogenic
foamy viruses may be a safe alternative for use in human
gene therapy.
MATERIALS AND METHODS
SFV-1 vector system
The construction of the SFV-1 vector plasmid pVC7-9 is
described elsewhere (Wu and Mergia, 1999). In pCV7-9,
the minimal human cytomegalovirus immediate-early
gene promoter was fused to the transcription start site
located in the R region of the 5LTR to direct high-level
vector transcription from 1 of the SFV-1 genome (Fig.
1). The CMV promoter used was the BamHI-SacI frag-
ment of pLNCX at position 2798–3516 (Miller and Ros-
man, 1989). The vector contains SFV-1 sequences from
the beginning of the R to the end of the pol gene, the
polypurine track (PPT), and the 3LTR. To monitor for the
efficiency of transduction, a LacZ gene under the control
of a CMV promoter is placed between the pol gene and
the PPT. Packaging plasmid (pCGPET) is derived by
deleting the tas gene from pCGPETH, which contained
the structural genes gag, pol, and env, and tas down-
stream from the CMV promoter (Park and Mergia, 2001;
Wu and Mergia, 1999). Splice donor of the 5SFV-1 is
provided between the CMV promoter and the gag gene
in pCGPET. The SV40 poly(A) signal sequence is sup-
plied at the 3 end. SFV-1 vector was produced by tran-
sient cotransfection of each vector plasmid pCV7-9 and
packaging plasmid pCGPETH with LipofectAMINE trans-
fection reagent (Gibco-BRL) as described previously
(Park and Mergia, 2001). The amounts of SFV-1 vectors
produced were titered on fresh 293T cells plated at a
density of 2.5  104 in 24 well plates. Forty-eight hours
after infection, cells were stained for -galactosidase
activity and positive cells were counted.
Cell culture
Human umbilical cord blood CD34 cells (94%
CD34) were obtained from BioWhittaker (Gaithersburg,
MD). CD34 cells (5  105) were transduced 2–3 times
for 5 h each in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 20% FBS (Hyclone, UT) con-
taining 100 ng/ml human Flt-3 ligand, 100 ng/ml human
stem cell factor, and 100 ng/ml human thrombopoietin
(Tpo) (Peprotech, Rocky Hill, NJ) on two wells of a fi-
bronectin-coated 24-well tissue culture plate under spi-
noculation conditions (1000 rpm) with an SFV-1 vector
(2–5  106 viral particles) containing the LacZ reporter
gene. In between transductions, the CD34 cells were
washed and cultured in IMDM supplemented with 20%
FBS containing the same concentration of growth factors
as described for the transduction. Following the last
transduction, 1.0–1.5  105 transduced CD34 cells
were transplanted by lateral tail vein injection into each
of 4–5 sublethally irradiated NOD/SCID mice as de-
scribed below. Transduced cells were also plated in
serum-free methylcellulose culture (Methocult SFBIT
H4436, StemCell Technologies, Vancouver, BC) in the
presence of 20 ng/ml human Flt-3 ligand, 50 ng/ml hu-
man stem cell factor, 20 ng/ml human GM-CSF, 20 ng/ml
human IL-3, 20 ng/ml human IL-6, and 3 units/ml human
erythropoietin (Epo) for 14 days at which time colonies
(50 cells) were scored. Colony morphology was deter-
mined by examining colonies under an inverted micro-
scope. All hematopoietic growth factors were obtained
from Peprotech. Briefly, cultures were stained for the
presence of -galactosidase activity by incubating at
37°C overnight with 5-bromo-4-chloro-3-indoyl--D-ga-
lactopyranososide (X-gal) at pH 8.2 (Morshead et al.,
2002). Staining for X-gal at this pH gave no nonspecific
staining in the control culture. Colonies were monitored
and scored for the appearance of blue staining using an
inverted microscope.
Mice
All transplants were performed with EMV30null NOD/
SCID mice (Serreze et al., 1995), originally purchased
from Jackson Labs (Bar Harbor, ME) and bred in our
animal facility. Four- to 5-week-old male and female
NOD/SCID mice were used. Animals were housed under
specific pathogen-free conditions in filter-top cages and
handled in sterile cross flows. Sterilized food and water
were given ad libitum. One to 3 h before grafting, the
animals were subjected to total body irradiation at a
dose of 3.0 cGy. Radiation was delivered in a Gamma
Cell 40 small animal irradiator (Atomic Energy of Canada,
Ottawa, Canada) equipped with two opposing cesium
137 -ray sources providing a homogenous dose distri-
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bution to the animals. Following irradiation, mice were
infused with 1.0–1.5  105 transduced human CD34
cells by tail vein injection. Mice received sterile food and
acidified sterile water and were injected with 1 g hu-
man G-CSF intraperitoneally every other day for a total of
four injections following transplantation.
Analysis of transplanted NOD/SCID mice
At 6–10 weeks posttransplantation, human hematopoi-
etic cell engraftment and marking were determined. Se-
rial bone marrow sampling for flow cytometry was ob-
tained from NOD/SCID mice as described by Verlinden
et al. (1998). Bone marrow cells were also obtained from
the femurs, tibias, and humori of mice that were sacri-
ficed by cervical dislocation by flushing with IMDM 5%
FBS. Red blood cells were lysed by a 5-min exposure
with a hypotonic ammonium chloride solution. The re-
maining nucleated cells were then prepared for flow
cytometry analysis, methylcellulose culture, or DNA and
RNA extraction for PCR and RT-PCR analysis. Briefly,
0.5–1.0  106 cells were stained with FITC-labeled CD45
antibody (Clone H130), PE-labeled CD19 antibody (Clone
HIB19), or PE-labeled CD33 antibody (Clone WM53) ob-
tained from BD Pharmingen (San Diego, CA) and ana-
lyzed using a FACSort machine (Becton Dickinson, San
Jose, CA) to determine the level of human cell engraft-
ment. FITC-labeled mouse IgG1 and PE-labeled mouse
IgG1 (Clone MOPC21) were used as controls and sub-
tracted from the CD45-positive and CD19- or CD33-pos-
itive values. Bone marrow cells (1.0  105) obtained from
each NOD/SCID mouse were also plated in serum-free
methylcellulose with human cytokines as described
above. Following 2 weeks of culture, the colonies were
stained and both X-gal-positive and X-gal-negative colo-
nies were enumerated.
Polymerase chain reaction
Genomic DNAs were constructed from bone marrow
cells by using a QIAamp DNA Mini kit (Qiagen, Inc.,
Valencia, CA) as instructed by the manufacturer and the
DNAs were analyzed by PCR. Briefly, 25 ng of genomic
DNA was amplified using a Taq polymerase and 40 pmol
of each primer. Primers for PCR were 5-GAT TGG TGG
CGA CGA CTC CTG-3 (forward, AYM86) and 5-CCG
AGT TTG TCA GAA AGC AGA CCA-3 (reverse, AYM87B)
selected from the 3 end of the coding sequence of the
LacZ gene region. The polymerase chain reaction was
performed for 30 cycles of denaturing at 94°C for 1 min,
annealing at 60°C for 2 min, and polymerization at 72°C
for 1.5 min. Ten microliters of each of the amplified
products was electrophoresed on a 1.2% agarose gel.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from bone marrow cells using
the Ambion RNA extraction kit (Austin, TX) and subse-
quently treated with RNAse-free DNAse. Half a micro-
gram of RNA was added to the reverse transcriptase
reaction using the Ambion RT-PCR kit and the AYM87B
primer as described by the manufacturer. The PCR was
performed for 30 cycles of denaturing at 94°C for 1 min,
annealing at 60°C for 2 min, and polymerization at 72°C
for 1.5 min with the addition of an opposing primer
(AYM86). Ten microliters of each of the products was
electrophoresed on a 1.2% agarose gel.
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